Content area
Full text
In a report, 38 patients (21 men and 13 women), aged 38-89 years [not all ages and sexes stated], were identified who developed acute (23 patients), chronic (14 patients), or aggravated (1 patient) renal failure following therapy with vemurafenib, ibuprofen, iodine, and piperacillin/tazobactam [c/osages and routes not stated].
All patients received only vemurafenib except 3 patients. These 3 patients received one other medication: ibuprofen, iodine, and piperacillin/tazobactam. All patients...